Status:
RECRUITING
MYeloma Resistance And Clonal Evolution
Lead Sponsor:
Nantes University Hospital
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Brief Summary
Multiple Myeloma (MM) is often associated with progression, temporary response to therapy and a high relapse rate over time resulting in a poor long-term prognosis. Because MM is classified as an incu...
Detailed Description
The MYRACLE cohort study aims at including all patients (\>18 years old) who are diagnosed with MM in any stage of the disease and treated in specialized oncology centers in 2 public hospitals in Nort...
Eligibility Criteria
Inclusion
- Patient consulting due to the discovery or recurrence of MM according to international diagnostic criteria (IMWG 2014)
- Patient having consented to participate in the study and his/her biocollection
- Patient affiliated to or benefiting from a social security scheme or similar
Exclusion
- Minors
- Major under guardianship or curatorship
- Protected persons.
- Pregnant or breast-feeding women
- Persons benefiting from the AME
Key Trial Info
Start Date :
February 11 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 11 2049
Estimated Enrollment :
1400 Patients enrolled
Trial Details
Trial ID
NCT03807128
Start Date
February 11 2019
End Date
February 11 2049
Last Update
July 14 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
La Roche sur Yon Hospital Departmental
La Roche-sur-Yon, France, 85000
2
Nantes University Hospital
Nantes, France, 44093